Results 261 to 270 of about 305,001 (288)

Acute Myeloid Leukemia

Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles, Armand, Keating, Anthony H, Goldstone, Irit, Avivi, Cheryl L, Willman, Hagop M, Kantarjian   +5 more
openaire   +2 more sources

Immunotherapy for Acute Myeloid Leukemia

Seminars in Hematology, 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S., Krupka, C., Köhnke, T., Subklewe, M.   +3 more
openaire   +3 more sources

Ivosidenib in acute myeloid leukemia

Expert Opinion on Pharmacotherapy, 2023
Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 ...
Bruzzese, Antonella, Labanca, Caterina, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Imovilli, Annalisa, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +10 more
openaire   +2 more sources

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, 2001
Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel, M R, Baer, D E, Hogge, R K, Stuart   +3 more
openaire   +2 more sources

Transplantation in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2014
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire   +2 more sources

Acute myeloid leukemia in adults

Current Treatment Options in Oncology, 2000
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire   +2 more sources

SEPHguarding acute myeloid leukemia

Cell Stem Cell, 2022
Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire   +2 more sources

Tipifarnib in acute myeloid leukemia

Drugs of Today, 2007
Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan K, Burnett, Jonathan, Kell
openaire   +2 more sources

Decitabine in Acute Myeloid Leukemia

Seminars in Hematology, 2005
Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire   +3 more sources

Pharmacogenomics in Acute Myeloid Leukemia

Pharmacogenomics, 2009
Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire   +2 more sources